8-K - BNBX - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):

September 19, 2023

Applied DNA Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware<br><br> <br>(State or other jurisdiction<br><br> <br>of incorporation)	001-36745<br><br> <br>(Commission File Number)	59-2262718<br><br> <br>(IRS Employer<br><br> <br>Identification No.)

50 Health Sciences Drive

Stony Brook, New York 11790

(Address of principal executive offices; zip code)

Registrant’s telephone number, including area code: ****

631-240-8800

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
---	---
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
---	---
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
---	---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	APDN	The<br>Nasdaq Stock Market
Item 5.07	Submission of Matters to a Vote of Security Holders.
---	---

On September 19, 2023, Applied DNA Sciences, Inc. (the “Company”) held its 2023 annual meeting of stockholders (the “2023 Annual Meeting”). The following proposals were voted on and were approved by the Company’s stockholders, except with respect to proposal 2 which was not approved, at the 2023 Annual Meeting with the stockholders having voted as set forth below:

I. To elect six directors to serve until the 2024 annual meeting of stockholders or until their respective successors are duly elected and qualified.


James A. Hayward	3,591,642	383,602	3,105,530
Robert B. Catell	3,572,859	402,385	3,105,530
Joseph D. Ceccoli	3,154,216	821,028	3,105,530
Yacov A. Shamash	3,005,706	969,538	3,105,530
Sanford R. Simon	3,514,258	460,986	3,105,530
Elizabeth Schmalz Shaheen	3,089,726	885,518	3,105,530

II. To approve an amendment to the Company’s 2020 Equity Incentive Plan, to increase the number of shares of common stock authorized for issuance by an additional 3,500,000.

FOR	AGAINST	ABSTAIN	BROKER NON-VOTES
2,520,302	1,368,359	86,583	3,105,530

III. To ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2023.

FOR	AGAINST	ABSTAIN
6,504,292	476,312	100,170

Each of the foregoing voting results from the 2023 Annual Meeting is final.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 20, 2023	APPLIED DNA SCIENCES, INC.
	By:	/s/ James A. Hayward
	Name:	James A. Hayward